Schizophrenia Clinical Trial
Official title:
PET Assay of Acetylcholine Beta2* Nicotinic Receptor Density in Smoking and Non-Smoking Schizophrenics
Background:
- Previous studies have suggested that smoking cigarettes affects the number of receptors in
the brain for nicotine, a chemical present in cigarette smoke. The receptors play a role in
an individual's ability to think and concentrate. Many people with schizophrenia and similar
disorders smoke, and research suggests that smoking may temporarily improve concentration and
focus in individuals with schizophrenia. Researchers are interested in studying both current
smokers and nonsmokers with schizophrenia to determine whether smoking affects the number of
nicotine receptors in the brains of people with schizophrenia.
Objectives:
- To study the distribution and volume of nicotine receptors in the brains of individuals
with schizophrenia who are either nonsmokers or current smokers.
Eligibility:
- Individuals between 18 and 50 years of age who have been diagnosed with schizophrenia
and are either nonsmokers or current smokers (at least 10 cigarettes per day for the
past year).
- Current smokers must be able to give up smoking for 48 hours.
Design:
- This study involves an initial screening visit and up to five study visits.
- After the screening visit, participants will have two sessions in which they will
complete questionnaires about thoughts, memory, and smoking habits. Smokers will also
have nicotine blood and carbon monoxide breath levels taken during these sessions,
before and after smoking a cigarette.
- Participants will have sessions with imaging studies (e.g., magnetic resonance imaging)
to provide baseline measurements for later tests, and will also have tests to measure
brain electrical activity.
- Participants will have a positron emission tomography (PET) scanning session to examine
the nicotine receptors in the brain. Participants will need to stay overnight
(nonsmokers) or for 2 nights (smokers) as an inpatient before the session. The PET scan
session will take up to 6 hours, although participants will only be in the scanner for
up to 3 hours.
- Participants will have a follow-up phone call with study researchers 1 week after the
PET scanning session.
Objective:
The objective of this study is to determine the distribution and volume of distribution (Vt)
in vivo of Beta2* acetylcholine receptors (Beta2* nAChR) in schizophrenic smokers and
nonsmokers and compare this to published data from normal healthy subjects who are smokers
and nonsmokers.
Study population:
Participants will be volunteers with a diagnosis of schizophrenia aged 18 to 50 years. The
proposed sample size is 10 per group: nonsmokers or ex-smokers and smokers for a total of 20
participants.
Design:
One PET study lasting up to 8 hours after combination of bolus and continuous infusion
administration of 2[(18)F] FA-85380. Smokers will be abstinent for at least 48 hrs. Subjects
will also undergo a structural MRI scan for purposes of registration of PET scan data.
Outcome Measures:
Data from 20 schizophrenic patients (10 smokers and 10 nonsmokers) will be compared to
published data from healthy controls. Total volume of distribution (VT) which is a measure of
receptor density and distribution of Beta2 nAChR* will be determined in Schizophrenic smokers
and nonsmokers and differences in these values will be compared to published values for the
differences in nicotinic acetylcholine receptor density in healthy smokers and nonsmokers
(Mukhin et al., 2008) Also, receptor distribution and VT will be correlated with levels of
smoking and symptom profiles in the schizophrenic patients studied.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |